Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma.
• A significant unmet need exists for effective therapies in the second and third-line treatment settings for DLBCL.
• Novel therapeutic strategies are crucial for improving outcomes in relapsed or refractory DLBCL.

Purpose of the Study:

• To review current treatment strategies for relapsed/refractory DLBCL.
• To discuss emerging novel therapies, including immunotherapies, for DLBCL.
• To highlight advancements in managing multiply-relapsed and heavily pre-treated DLBCL patients.

Main Methods:

• Review of recent clinical studies and emerging therapies for DLBCL.
• Analysis of data on immunochemotherapies, CAR T-cells, antibody-drug conjugates (ADCs), and small molecule inhibitors.
• Evaluation of treatment efficacy in heavily pre-treated and multiply-relapsed DLBCL populations.

Main Results:

• Emerging immunochemotherapies demonstrate activity in small studies, with some patients achieving prolonged remissions.
• Anti-CD19 CAR T-cells show potential for curative treatment in later lines of therapy.
• Antibody-drug conjugates like polatuzumab vedotin and agents such as tafasitamab and selinexor exhibit effectiveness in relapsed/refractory DLBCL.

Conclusions:

• Novel therapies, including CAR T-cells, ADCs, and targeted agents, are transforming the treatment landscape for relapsed/refractory DLBCL.
• These advancements offer new hope for prolonged remissions and potentially curative options for patients with limited prior treatment success.
• Further investigation and integration of these novel agents are essential for optimizing DLBCL management.